SUCCESSFUL CLINICAL STUDY OF LENIOLISIB (CDZ173), A SMALL MOLECULE PI3K-DELTA INHIBITOR, IN PATIENTS WITH APDS/PASLI

被引：0
|
作者：
Rao, V. Koneti [1 ]
Christ, Andreas [2 ]
Su, Hua [1 ]
Kashyap, Anuj [1 ]
Webster, Sharon [1 ]
Sediva, Anna [3 ]
Dalm, Virgil A. S. H. [4 ]
Van Hagen, P. Martin [4 ]
Sloth, Birgitte [5 ]
Lenardo, Michael J. [6 ]
Cabanski, Maciej [7 ]
Burkhart, Christoph [7 ]
Uzel, Gulbu [1 ]
机构：
[1] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[2] Novartis Inst Biomed Res, Basel, Switzerland
[3] Charles Univ Prague, Fac Med 2, Motol Univ Hosp, Dept Immunol, Prague, Czech Republic
[4] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands
[5] Novartis Pharma AG, NIBR, TM, CS&I, Basel, Switzerland
[6] NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA
[7] Novartis Pharma AG, Basel, Switzerland
来源：
JOURNAL OF CLINICAL IMMUNOLOGY | 2017年 / 37卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
5139
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [1] Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
    Hoegenauer, Klemens
    Soldermann, Nicolas
    Zecri, Frederic
    Strang, Ross S.
    Grayeleau, Nadege
    Wolf, Romain M.
    Cooke, Nigel G.
    Smith, Alexander B.
    Hollingworth, Gregory J.
    Blanz, Joachim
    Gutmann, Sascha
    Rummel, Gabriele
    Littlewood-Evans, Amanda
    Burkhart, Christoph
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (09): : 975 - 980
  • [2] Design of A Metabolically Stable Tritium-Tracer of the PI3K-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites
    Bauer, Carsten
    Luu, Tong
    Eggimann, Fabian
    Bross, Patrick
    Gertsch, Werner
    Hu, Cheng
    Ramstein, Philippe
    Bourgailh, Julien
    Glanzel, Albrecht
    Dix, Ina
    Guenat, Christian
    Soldermann, Nicolas
    Litherland, Karine
    Desrayaud, Sandrine
    Hengy, Jean-Claude
    Pearson, David
    Blanz, Joachim
    Burkhart, Christoph
    HELVETICA CHIMICA ACTA, 2018, 101 (06)
  • [3] Phase 3 Placebo-Controlled, Randomized Clinical Trial Outcomes of PI3K Delta Inhibitor Leniolisib in Patients with Activated PI3K Delta Syndrome (APDS/PASLI)
    Rao, V. Koneti
    Webster, Sharon
    Sediva, Anna
    Plebani, Alessandro
    Schuetz, Catharina
    Shcherbina, Anna
    Conlon, Niall
    Coulter, Tanya
    Dalm, Virgil
    Trizzino, Antonino
    Zharankova, Yulia
    Kulm, Elaine
    Koerholz, Julia
    Lougaris, Vassilios
    Rodina, Yulia
    Kucher, Klaus
    Radford, Kath
    Bradt, Jason
    Uzel, Gulbu
    JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) : S4 - S5
  • [4] Safety and Efficacy of Long Term Suppression of PI3Kinase Pathway By Small Molecule PI3K-Delta Inhibitor, Leniolisib in Apds (Activated PI3Kδ Syndrome)
    Rao, V. Koneti
    Webster, Sharon
    Dalm, Virgil A. S. H.
    Sediva, Anna
    van Hagen, P. Martin
    Do, H. Michael
    Folio, Les
    Cabanski, Maciej
    Valentin, Marie-Anne
    de Buck, Stefan
    Kalis, Christoph
    Hasselberg, Anke
    Burkhart, Christoph
    Kucher, Klaus
    Sloth, Birgitte
    Uzel, Gulbu
    BLOOD, 2018, 132
  • [5] Discovery of leniolisib (CDZ173), a potent and selective new generation PI3Kdelta inhibitor for autoimmune and inflammatory diseases
    Soldermann, Nicolas
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [6] 19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers
    Pearson, David
    Garnier, Maxime
    Luneau, Alexandre
    James, Alexander David
    Walles, Markus
    XENOBIOTICA, 2019, 49 (08) : 953 - 960
  • [7] Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): an externally controlled study
    Whalen, John
    Chandra, Anita
    Kracker, Sven
    Ehl, Stephan
    Seidel, Markus G.
    Gulas, Ioana
    Dron, Louis
    Velummailum, Russanthy
    Nagamuthu, Chenthila
    Liu, Sichen
    Nolthenius, Joanne Tutein
    Maccari, Maria Elena
    European Soc for Immunodeficiencies ESID APDS Registry Working Party
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2024,
  • [8] Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis
    Wu, Zuoxing
    Li, Xuedong
    Chen, Xiaohui
    He, Xuemei
    Chen, Yu
    Zhang, Long
    Li, Zan
    Yang, Mengyu
    Yuan, Guixin
    Shi, Baohong
    Chen, Ning
    Li, Na
    Feng, Haotian
    Zhou, Mengyu
    Rui, Gang
    Xu, Feng
    Xu, Ren
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [9] The Clinical Manifestations, Management and Outcomes of Activated PI3K-Delta Syndrome (APDS) in UK and Ireland Cohort
    Coulter, T. I.
    Chandra, A.
    Leahy, T. R.
    Curtis, J.
    Bacon, C. M.
    Babar, J.
    Farmer, G.
    Savic, S.
    Burns, S. O.
    Jones, A. M.
    Gavin, P. J.
    Feighery, C. F.
    Forsyth, P.
    Herriot, R.
    Edgar, J. D.
    Abinun, M.
    Markelj, G.
    Ibrahim, M.
    Baxendale, H.
    Doffinger, R.
    Kumararatne, D.
    Condliffe, A. M.
    Cant, A. J.
    Nejentsev, S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S163 - S163
  • [10] EARLY CLINICAL ACTIVITY AND PHARMACODYNAMIC EFFECTS OF DUVELISIB, A PI3K-DELTA, GAMMA INHIBITOR, IN PATIENTS WITH TREATMENT-NAIVE CLL
    O'Brien, S.
    Faia, K.
    White, K.
    Douglas, M.
    Allen, K.
    Kutok, J.
    Sweeney, J.
    Kelly, V.
    Flinn, I.
    Byrd, J.
    Stern, H.
    HAEMATOLOGICA, 2015, 100 : 154 - 155
12345